Hanania NA, et al. - Fractional exhaled nitric oxide (FeNO) is a recognized biomarker of type 2 airway inflammation in asthma. In real-world clinical practices, the impact of FeNO assessment on asthma management was assessed. Relative to real-world clinical assessment of asthma alone, measurement of FeNO enabled clinicians to assess underlying airway inflammation leading to a significant revision of their treatment plans.